Research programme: fibrosis therapeutics - Excaliard Pharmaceuticals

Drug Profile

Research programme: fibrosis therapeutics - Excaliard Pharmaceuticals

Alternative Names: Anti-fibrotic antisense drugs - Excaliard Pharmaceuticals

Latest Information Update: 29 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Excaliard Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Fibrosis; Scars

Most Recent Events

  • 29 Mar 2012 No development reported for Fibrosis in USA (unspecified route)
  • 29 Mar 2012 No development reported for Scars in USA (unspecified route)
  • 02 Dec 2011 Excaliard Pharmaceuticals has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top